Literature DB >> 22669612

BDNF and DYRK1A are variable and inversely correlated in lymphoblastoid cell lines from Down syndrome patients.

Asma Tlili1, Alexander Hoischen, Clémentine Ripoll, Eva Benabou, Anne Badel, Anne Ronan, Renaud Touraine, Yann Grattau, Samantha Stora, Bregje van Bon, Bert de Vries, Björn Menten, Nele Bockaert, Joseph Gecz, Stylianos E Antonarakis, Dominique Campion, Marie-Claude Potier, Henri Bléhaut, Jean-Maurice Delabar, Nathalie Janel.   

Abstract

Down syndrome or trisomy 21 is the most common genetic disorder leading to mental retardation. One feature is impaired short- and long-term spatial memory, which has been linked to altered brain-derived neurotrophic factor (BDNF) levels. Mouse models of Down syndrome have been used to assess neurotrophin levels, and reduced BDNF has been demonstrated in brains of adult transgenic mice overexpressing Dyrk1a, a candidate gene for Down syndrome phenotypes. Given the link between DYRK1A overexpression and BDNF reduction in mice, we sought to assess a similar association in humans with Down syndrome. To determine the effect of DYRK1A overexpression on BDNF in the genomic context of both complete trisomy 21 and partial trisomy 21, we used lymphoblastoid cell lines from patients with complete aneuploidy of human chromosome 21 (three copies of DYRK1A) and from patients with partial aneuploidy having either two or three copies of DYRK1A. Decreased BDNF levels were found in lymphoblastoid cell lines from individuals with complete aneuploidy as well as those with partial aneuploidies conferring three DYRK1A alleles. In contrast, lymphoblastoid cell lines from individuals with partial trisomy 21 having only two DYRK1A copies displayed increased BDNF levels. A negative correlation was also detected between BDNF and DYRK1A levels in lymphoblastoid cell lines with complete aneuploidy of human chromosome 21. This finding indicates an upward regulatory role of DYRK1A expression on BDNF levels in lymphoblastoid cell lines and emphasizes the role of genetic variants associated with psychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22669612     DOI: 10.1007/s12035-012-8284-7

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  28 in total

1.  Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome.

Authors:  Patrizia Bianchi; Elisabetta Ciani; Sandra Guidi; Stefania Trazzi; Daniela Felice; Gabriele Grossi; Mercedes Fernandez; Alessandro Giuliani; Laura Calzà; Renata Bartesaghi
Journal:  J Neurosci       Date:  2010-06-30       Impact factor: 6.167

2.  Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.

Authors:  X Altafaj; M Dierssen; C Baamonde; E Martí; J Visa; J Guimerà; M Oset; J R González; J Flórez; C Fillat; X Estivill
Journal:  Hum Mol Genet       Date:  2001-09-01       Impact factor: 6.150

3.  Protein kinase Dyrk1 activates cAMP response element-binding protein during neuronal differentiation in hippocampal progenitor cells.

Authors:  E J Yang; Y S Ahn; K C Chung
Journal:  J Biol Chem       Date:  2001-08-22       Impact factor: 5.157

4.  Association of a functional BDNF polymorphism and anxiety-related personality traits.

Authors:  Undine E Lang; Rainer Hellweg; Peter Kalus; Malek Bajbouj; Kirsten P Lenzen; Thomas Sander; Dieter Kunz; Jürgen Gallinat
Journal:  Psychopharmacology (Berl)       Date:  2005-01-26       Impact factor: 4.530

Review 5.  Brain-derived neurotrophic factor: a newly described mediator of angiogenesis.

Authors:  Pouneh Kermani; Barbara Hempstead
Journal:  Trends Cardiovasc Med       Date:  2007-05       Impact factor: 6.677

Review 6.  Neurotrophin-dependent modulation of glutamatergic synaptic transmission in the mammalian CNS.

Authors:  V Lessmann
Journal:  Gen Pharmacol       Date:  1998-11

7.  Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes.

Authors:  E Aït Yahya-Graison; J Aubert; L Dauphinot; I Rivals; M Prieur; G Golfier; J Rossier; L Personnaz; N Creau; H Bléhaut; S Robin; J M Delabar; M-C Potier
Journal:  Am J Hum Genet       Date:  2007-07-19       Impact factor: 11.025

8.  Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

Authors:  M Kerschensteiner; E Gallmeier; L Behrens; V V Leal; T Misgeld; W E Klinkert; R Kolbeck; E Hoppe; R L Oropeza-Wekerle; I Bartke; C Stadelmann; H Lassmann; H Wekerle; R Hohlfeld
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

9.  Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters.

Authors:  Priit Pruunsild; Anna Kazantseva; Tamara Aid; Kaia Palm; Tõnis Timmusk
Journal:  Genomics       Date:  2007-07-12       Impact factor: 5.736

10.  Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A.

Authors:  Fayçal Guedj; Catherine Sébrié; Isabelle Rivals; Aurelie Ledru; Evelyne Paly; Jean C Bizot; Desmond Smith; Edward Rubin; Brigitte Gillet; Mariona Arbones; Jean M Delabar
Journal:  PLoS One       Date:  2009-02-26       Impact factor: 3.240

View more
  10 in total

1.  DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients.

Authors:  Manon Moreau; Maria Carmona-Iragui; Miren Altuna; Lorraine Dalzon; Isabel Barroeta; Marie Vilaire; Sophie Durand; Juan Fortea; Anne-Sophie Rebillat; Nathalie Janel
Journal:  Biomedicines       Date:  2022-06-10

2.  Intracisternal Gtf2i Gene Therapy Ameliorates Deficits in Cognition and Synaptic Plasticity of a Mouse Model of Williams-Beuren Syndrome.

Authors:  Cristina Borralleras; Ignasi Sahun; Luis A Pérez-Jurado; Victoria Campuzano
Journal:  Mol Ther       Date:  2015-07-28       Impact factor: 11.454

3.  Validation of microarray data in human lymphoblasts shows a role of the ubiquitin-proteasome system and NF-kB in the pathogenesis of Down syndrome.

Authors:  Barbara Granese; Iris Scala; Carmen Spatuzza; Anna Valentino; Marcella Coletta; Rosa Anna Vacca; Pasquale De Luca; Generoso Andria
Journal:  BMC Med Genomics       Date:  2013-07-05       Impact factor: 3.063

4.  Plasma DYRK1A as a novel risk factor for Alzheimer's disease.

Authors:  N Janel; M Sarazin; F Corlier; H Corne; L C de Souza; L Hamelin; A Aka; J Lagarde; H Blehaut; V Hindié; J-C Rain; M L Arbones; B Dubois; M C Potier; M Bottlaender; J M Delabar
Journal:  Transl Psychiatry       Date:  2014-08-12       Impact factor: 6.222

5.  Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome.

Authors:  Martina Parrini; Diego Ghezzi; Gabriele Deidda; Lucian Medrihan; Enrico Castroflorio; Micol Alberti; Pietro Baldelli; Laura Cancedda; Andrea Contestabile
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

6.  Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease.

Authors:  N Janel; P Alexopoulos; A Badel; F Lamari; A C Camproux; J Lagarde; S Simon; C Feraudet-Tarisse; P Lamourette; M Arbones; J L Paul; B Dubois; M C Potier; M Sarazin; J M Delabar
Journal:  Transl Psychiatry       Date:  2017-06-20       Impact factor: 6.222

7.  Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome.

Authors:  Syed Faraz Kazim; Julie Blanchard; Riccardo Bianchi; Khalid Iqbal
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

8.  Ultrastructural and dynamic studies of the endosomal compartment in Down syndrome.

Authors:  Alexandra Botté; Jeanne Lainé; Laura Xicota; Xavier Heiligenstein; Gaëlle Fontaine; Amal Kasri; Isabelle Rivals; Pollyanna Goh; Orestis Faklaris; Jack-Christophe Cossec; Etienne Morel; Anne-Sophie Rebillat; Dean Nizetic; Graça Raposo; Marie-Claude Potier
Journal:  Acta Neuropathol Commun       Date:  2020-06-24       Impact factor: 7.801

9.  Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain.

Authors:  Md Mahiuddin Ahmed; A Ranjitha Dhanasekaran; Suhong Tong; Frances K Wiseman; Elizabeth M C Fisher; Victor L J Tybulewicz; Katheleen J Gardiner
Journal:  Hum Mol Genet       Date:  2013-01-24       Impact factor: 6.150

10.  The burden of trisomy 21 disrupts the proteostasis network in Down syndrome.

Authors:  Stefanos Aivazidis; Christina M Coughlan; Abhishek K Rauniyar; Hua Jiang; L Alexander Liggett; Kenneth N Maclean; James R Roede
Journal:  PLoS One       Date:  2017-04-21       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.